Prenetics Global Appoints Experienced CFO for Rapidly Expanding IM8 Subsidiary
PRE has more than doubled off its 52-week low of $5.1.
Summary
Prenetics Global's key growth subsidiary, IM8, has appointed Brian J. Rosin as its new Chief Financial Officer, bringing two decades of relevant financial leadership experience to support its rapid global expansion.
Key Events · Executive and Board Changes · PRE
-
New CFO for IM8 Subsidiary
Brian J. Rosin has been appointed as the Chief Financial Officer of IM8, Prenetics Global's premium health and longevity brand.
-
Experienced Financial Leader
Mr. Rosin brings nearly two decades of financial leadership experience in consumer e-commerce, premium wellness, and subscription brands, with a focus on scaling operations and unit economics.
-
Supports Rapid Global Expansion
The appointment establishes dedicated finance leadership for IM8 to support its rapid global expansion across more than 40 countries and its projected $190 million to $210 million in revenue for full year 2026.
Analysis · PRE · Industrial Applications And Services
Prenetics Global has appointed Brian J. Rosin as the Chief Financial Officer for its IM8 subsidiary. This is a significant hire given IM8's rapid global expansion and its projected revenue of $190 million to $210 million for 2026, making it a core growth driver for the parent company. Mr. Rosin's extensive background in consumer e-commerce and premium wellness brands is crucial for scaling IM8's financial operations and ensuring disciplined growth.
At the time of this filing, PRE was trading at $17.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $295.7M. The 52-week trading range was $5.10 to $23.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.